1. At a Glance
A ₹3,758 Cr pharma company with roots in anti-TB API fermentation, Gujarat Themis Biosyn has been compounding silently with 45%+ OPM and healthy ROE. But a PE of 77 and shrinking growth say: “Fermentation toh hai, lekin fizz thoda kam hai.”
2. Introduction with Hook
If you’ve ever wondered what happens when India’s first rifampicin producer, a Hungarian pharma giant, and a South Korean technical partner walk into a bioreactor — Gujarat Themis is your punchline.
- FY25 PAT: ₹49 Cr
- Operating Margins: 46%
- Sales growth? Nah, it’s actually shrinking 11% YoY
This one’s not a rocketship. It’s a slowly aging oak barrel of fermentation-based profitability — smooth, but not spicy.
3. Business Model (WTF Do They Even Do?)
GTBL specializes in fermentation-based Active Pharmaceutical Ingredients (APIs). Key differentiators:
- Anti-TB drugs: India’s first commercial rifampicin producer
- Tech collab: With Yuhan (Korea) + Themis Medicare (India)
- Core Capability: Biotech-based API production (as opposed to synthetic)
- New Plant in Vapi: US & EU-compliant expansion
- No formulations, only B2B APIs
It’s
